Bacterial Susceptibilities to Piperacillin/Tazobactam in a Tertiary Care Hospital: 5-Year Review
Authors:
- N.P. ZissisNZN.P. Zissis
- J. PortolosJPJ. Portolos
- O. PaniaraOPO. Paniara
- 1 January 2003
- journal article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 15 (1) , 27-30
Abstract
Several factors influence the speed of development of antibacterial resistance, among which is the amount of antibiotic consumption. During the 3-year period 1998-2000, the consumption of piperacillin/tazobactam (pip/tazo) increased by 85% in our hospital. Five years ago we conducted a comparative in vitro study to evaluate susceptibilities of microorganisms to pip/tazo. The objective of the present study was to re-evaluate in vitro susceptibilities to pip/tazo, compared to other beta-lactams, and the potential impact its increased consumption might have on its susceptibility patterns. The study was performed between November 2000 and April 2001. As in 1996, of the beta-lactams studied, pip/tazo and imipenem had the highest susceptibility rates against selected pathogens (>90% susceptibility rates). P. aeruginosa susceptibilities to both imipenem and pip/tazo were high (97% for both). P. aeruginosa susceptibilities to cefepime were lower. Despite its increased use, pip/tazo retained its initially observed high susceptibility rates for the study pathogens.Keywords
This publication has 6 references indexed in Scilit:
- An Observational Study on the Epidemiology of Respiratory Tract Bacterial Pathogens and Their Susceptibility to Four Injectable Beta-Lactam Antibiotics: Piperacillin, Piperacillin/Tazobactam, Ceftazidime and CeftriaxoneJournal of Chemotherapy, 2001
- Surveillance de la sensibilité de Pseudomonas aeruginosa aux antibiotiques en France et distribution des mécanismes de résistance aux bêtalactamines : étude GERPB 1999Pathologie Biologie, 2001
- Association of Antibiotic Utilization Measures and Control of Multiple-Drug Resistance inKlebsiella pneumoniaeInfection Control & Hospital Epidemiology, 2000
- In VitroActivity of Piperacillin/Tazobactam Versus Other Broad-Spectrum Antibiotics Against Nosocomial Gram-Negative Pathogens Isolated from Burn PatientsJournal of Chemotherapy, 1998
- ComparativeIn VitroEvaluation of Piperacillin/Tazobactam in a Tertiary Care HospitalJournal of Chemotherapy, 1997
- Escherichia coli Resistant to Fluoroquinolones in Patients with Cancer and NeutropeniaNew England Journal of Medicine, 1994